ArriVent's lead lung cancer drug fails Phase 3, shares collapse

· Health · United States · China

ArriVent BioPharma reported that its lead lung cancer drug, firmonertinib, failed a key late-stage Phase 3 trial. Firmonertinib is an EGFR inhibitor that was first approved for lung cancer in China, and ArriVent was an early adopter of the China licensing model, in which Western biotechs license drug candidates developed by Chinese companies. The disappointing data wiped out more than half of the company's value, according to BioPharma Dive. The failure appears to erase ArriVent's chance to compete against Johnson & Johnson and others for market share in the same lung cancer indication. The result is a significant setback for the company and a blow to the broader cross-border licensing strategy that has become a major source of pipeline assets for US and European drugmakers in recent years.

Why it matters：The trial failure is a high-profile test of the China licensing model that has become a key pipeline strategy for Western drugmakers, and its collapse could make investors and partners more cautious about similar deals.

Key points

  • Firmonertinib is an EGFR inhibitor first approved for lung cancer in China.
  • ArriVent was an early adopter of the China licensing model for drug development.
  • More than half of the company's value was wiped out by the data.

Sources (original reporting)

More stories from this day